ResMed Divests MatrixCare Software Business to Frazier Healthcare Partners
RMD sits 21% above its 52-week low of $180.265.
Summary
ResMed has entered a definitive agreement to sell its MatrixCare cloud-based EHR software business to Frazier Healthcare Partners. This divestiture is described by ResMed's CEO as a strategic move aligned with the company's 2030 strategy for focused portfolio management. While financial terms were not disclosed, the sale of a leading healthcare software provider will impact ResMed's future revenue streams and strategic focus. The transaction is expected to close during the third quarter of 2026.
At the time of this announcement, RMD was trading at $218.92 on NYSE in the Life Sciences sector, with a market capitalization of approximately $31.9B. The 52-week trading range was $180.27 to $293.81. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.